Physician profile

Monica A Gomberg

Endocrinology, Diabetes & Metabolism · Boston, MA

NPI 1780983148

$1,917.00

in general payments reported to CMS, 2019-2025

6 companies · $150 in 2025

The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

See the full distribution for Endocrinology, Diabetes & Metabolism

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$150.00
Food and Beverage$115.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic Minimed, INC. $1,513.98 2019
Sanofi-Aventis U.S. LLC $265.77 2024-2025
Abbott Laboratories $54.72 2020-2022
Novo Nordisk INC $51.94 2022
Insulet Corporation $18.26 2022
Xeris Pharmaceuticals, INC. $12.33 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Monica A Gomberg

$1,917.00

in general payments reported 2019-2025

Years
2019-2025
Top company
Medtronic Minimed, INC.
Context
The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/1381035/monica-a-gomberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.